Engineering donor-derived CAR-CIK cells towards B-ALL multi-targeting using Sleeping Beauty platform
Alex Moretti, MD, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, discusses the development of multi-targeting donor-derived CAR cytokine-induced-killer (CAR-CIK) cells using the non-viral Sleeping Beauty (SB) transposon platform, for the prevention and treatment of B-cell acute lymphoblastic leukemia (B-ALL) relapses. These CAR-CIK cells were engineered to target the CD22 and BAFF-R antigens to treat patients with CD19-negative disease following relapse. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.